Literature DB >> 26265346

Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.

Linda M Henricks1,2, Carin A T C Lunenburg3, Didier Meulendijks1,2, Hans Gelderblom3, Annemieke Cats4, Jesse J Swen5, Jan H M Schellens1,2,6, Henk-Jan Guchelaar5.   

Abstract

The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a key role in the metabolism of fluoropyrimidines. DPD deficiency occurs in 4-5% of the population and is associated with severe fluoropyrimidine-related toxicity. Several SNPs in DPYD have been described that lead to absent or reduced enzyme activity, including DPYD*2A, DPYD*13, c.2846A>T and c.1236G>A/haplotype B3. Since these SNPs differ in their effect on DPD enzyme activity, a differentiated dose adaption is recommended. We propose the gene activity score for translating DPYD genotype into phenotype, accounting for differences in functionality of SNPs. This method can be used to standardize individualized fluoropyrimidine dose adjustments, resulting in optimal safety and effectiveness.

Entities:  

Keywords:  5-fluorouracil; DPYD; capecitabine; dihydropyrimidine dehydrogenase; fluoropyrimidines; gene activity score; individualized medicine; pharmacogenomics

Mesh:

Substances:

Year:  2015        PMID: 26265346     DOI: 10.2217/pgs.15.70

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  23 in total

Review 1.  Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Authors:  Jan H Beumer; Edward Chu; Carmen Allegra; Yusuke Tanigawara; Gerard Milano; Robert Diasio; Tae Won Kim; Ron H Mathijssen; Li Zhang; Dirk Arnold; Katsuki Muneoka; Narikazu Boku; Markus Joerger
Journal:  Clin Pharmacol Ther       Date:  2018-09-11       Impact factor: 6.875

Review 2.  DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2021-08-12

3.  Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population.

Authors:  Mohammad Salmani; Bayazid Ghaderi; Alan Fotoohi; Ramtin Omid-Shafa'at; Zakaria Vahabzadeh; Omid Fotouhi; Mohammad Abdi
Journal:  Cancer Chemother Pharmacol       Date:  2022-09-09       Impact factor: 3.288

4.  Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population.

Authors:  Eiji Hishinuma; Yoko Narita; Kai Obuchi; Akiko Ueda; Sakae Saito; Shu Tadaka; Kengo Kinoshita; Masamitsu Maekawa; Nariyasu Mano; Noriyasu Hirasawa; Masahiro Hiratsuka
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

5.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

Authors:  Ursula Amstutz; Linda M Henricks; Steven M Offer; Julia Barbarino; Jan H M Schellens; Jesse J Swen; Teri E Klein; Howard L McLeod; Kelly E Caudle; Robert B Diasio; Matthias Schwab
Journal:  Clin Pharmacol Ther       Date:  2017-11-20       Impact factor: 6.875

Review 6.  Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.

Authors:  P C D Bank; K E Caudle; J J Swen; R S Gammal; M Whirl-Carrillo; T E Klein; M V Relling; H-J Guchelaar
Journal:  Clin Pharmacol Ther       Date:  2017-10-10       Impact factor: 6.875

Review 7.  Therapeutic drug monitoring of 5-fluorouracil.

Authors:  James J Lee; Jan H Beumer; Edward Chu
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-23       Impact factor: 3.333

8.  Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression.

Authors:  Qi Chen; Yong Mao; Fanyi Meng; Lei Wang; Hongjian Zhang; Weipeng Wang; Dong Hua
Journal:  Oncotarget       Date:  2017-07-28

9.  The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.

Authors:  Angkana Thongkum; Chunjing Wu; Ying-Ying Li; Medhi Wangpaichitr; Panida Navasumrit; Varabhorn Parnlob; Thaniya Sricharunrat; Vajarabhongsa Bhudhisawasdi; Mathuros Ruchirawat; Niramol Savaraj
Journal:  Int J Mol Sci       Date:  2017-06-01       Impact factor: 5.923

10.  Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.

Authors:  Linda M Henricks; Bart A W Jacobs; Didier Meulendijks; Dick Pluim; Daan van den Broek; Niels de Vries; Hilde Rosing; Jos H Beijnen; Alwin D R Huitema; Henk-Jan Guchelaar; Annemieke Cats; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2018-09-25       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.